Insulet Corporation (PODD)
NASDAQ: PODD · IEX Real-Time Price · USD
166.19
+2.02 (1.23%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Insulet Employees
Insulet had 3,000 employees on December 31, 2023. The number of employees increased by 400 or 15.38% compared to the previous year.
Employees
3,000
Change (1Y)
400
Growth (1Y)
15.38%
Revenue / Employee
$565,700
Profits / Employee
$68,767
Market Cap
11.64B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3,000 | 400 | 15.38% |
Dec 31, 2022 | 2,600 | 300 | 13.04% |
Dec 31, 2021 | 2,300 | 400 | 21.05% |
Dec 31, 2020 | 1,900 | 550 | 40.74% |
Dec 31, 2019 | 1,350 | 181 | 15.48% |
Dec 31, 2018 | 1,169 | 312 | 36.41% |
Dec 31, 2017 | 857 | 217 | 33.91% |
Dec 31, 2016 | 640 | -7 | -1.08% |
Dec 31, 2015 | 647 | 128 | 24.66% |
Dec 31, 2014 | 519 | 41 | 8.58% |
Dec 31, 2013 | 478 | -60 | -11.15% |
Dec 31, 2012 | 538 | -38 | -6.60% |
Dec 31, 2011 | 576 | 266 | 85.81% |
Dec 31, 2010 | 310 | 34 | 12.32% |
Dec 31, 2009 | 276 | -18 | -6.12% |
Dec 31, 2008 | 294 | 47 | 19.03% |
Dec 31, 2007 | 247 | -47 | -15.99% |
Dec 31, 2006 | 294 | 47 | 19.03% |
Dec 31, 2005 | 247 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG & Co. KGaA | 119,845 |
DaVita | 70,000 |
Dr. Reddy's Laboratories | 25,863 |
Charles River Laboratories International | 21,800 |
Bruker | 9,707 |
Medpace Holdings | 5,900 |
Incyte | 2,524 |
ShockWave Medical | 1,468 |
PODD News
- 24 days ago - Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024 - Business Wire
- 24 days ago - Nadav Eiron Joins Crusoe as Senior Vice President of Cloud Engineering - Business Wire
- 5 weeks ago - Insulet Appoints Ana Maria Chadwick as Chief Financial Officer - Business Wire
- 7 weeks ago - Insulet's Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy - Business Wire
- 7 weeks ago - Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) - Business Wire
- 2 months ago - Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency) - Business Wire
- 2 months ago - Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference - Business Wire
- 2 months ago - Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor - Business Wire